Jefferies keeps EUR 16 target for Almirall stock

Published on 10/13/2026 at 06:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 7.50 percent to EUR 602.70 million in 2026. For Almirall stock this means first-half EBITDA of EUR 150.70 million.

Key points in brief

Jefferies kept a EUR 16.00 price target for Almirall on October 11, 2026.
First-half 2026 net sales rose 7.50 percent to EUR 602.70 million.
Almirall's last Lang & Schwarz price was EUR 9.88 on October 12, 2026.
Nine-month 2026 results are scheduled for November 9, 2026.

Isometrische 3D-Illustration einer Pharma-Wertschöpfungskette von Labor bis Lieferwagen — Almirall S.A. (ES0157097017) veranschaulicht isometrisch die Pharma-Wertschöpfungskette von Labor bis Vertrieb detailliert, Illustration mit AI erstellt.

Almirall (ISIN ES0157097017) had Jefferies keep a EUR 16.00 price target on October 11, 2026, according to Merca2. The research view combines expected Ebglyss acceleration with a regulatory risk in Germany.

Three milestones shape the story

On July 24, 2026, Almirall reported first-half net sales of EUR 602.70 million, up 7.50 percent year over year, while earnings before interest, taxes, depreciation and amortization rose 23.70 percent to EUR 150.70 million, according to Business Wire.

On September 30, 2026, Almirall presented more than 20 abstracts at the European Academy of Dermatology and Venereology congress, including long-term data for lebrikizumab, as Business Wire reported.

On October 11, 2026, Jefferies maintained its positive view and the EUR 16.00 target. The target is 61.62 percent above the last Lang & Schwarz price of EUR 9.88, but that calculation compares an analyst target with a dated market quote rather than a guaranteed return.

What does the German risk mean?

Merca2 reported that Jefferies viewed the German reimbursement reform as the main risk to forecasts from 2027. The article cited a possible increase in the discount burden from 7.00 percent to 15.50 percent, while Jefferies estimated a 2.35 percent impact on Almirall's total sales.

The investment case therefore has two measurable sides: first-half net sales growth of 7.50 percent and a 23.70 percent increase in EBITDA, against a regulatory scenario that could reduce future sales. The next reported figures will provide a clearer test of whether Ebglyss growth is accelerating in Europe.

Results dates set the next checkpoints

Almirall's investor calendar lists nine-month 2026 financial results for November 9, 2026 and full-year 2026 results for February 22, 2027, according to the company's investor-relations page. Those dates are the next scheduled checkpoints for sales, EBITDA and the Ebglyss launch.

Almirall was last at EUR 9.88 at Lang & Schwarz on October 12, 2026 at 10:58 p.m. CEST. Its market capitalization was EUR 2.2 billion on October 12, 2026, and the 52-week range was EUR 9.84 to EUR 13.98.

The further course of trading is shown by the continuously updated real-time quote of Almirall stock.